🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hidradenitis

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% NCT06645821EARLY Phase 11 site📍 Norfolk Virginia Clinical Research, Inc. · Tests: EVO101 Battlefield Acupuncture for Pain in Hidradenitis Suppurativa NCT04218422NA1 site📍 Dearborn Wayne State University · Tests: Battlefield Acupuncture, Sham Acupuncture SAR447971 First-in-human Study NCT07629336Phase 11 site📍 Leiden Sanofi · Tests: SAR447971, Placebo A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients NCT06946641Phase 11 site📍 Beijing Shanghai Qilu Pharmaceutical Research and Development Cente… · Tests: QLS12010, Placebo Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population NCT07543419n/a16 sites📍 Ancona📍 Bari📍 Brescia Novartis Pharmaceuticals Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa NCT07828860Phase 111 sites📍 West Lafayette📍 Bowling Green📍 Owensboro Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa NCT07136467n/a116 sites📍 Ciudad Autonoma de Buenos Aire📍 Buenos Aires📍 Buenos Aires AbbVie SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa NCT07225569Phase 286 sites📍 Scottsdale📍 North Hollywood📍 Boynton Beach Sanofi · Tests: SAR445399, Placebo Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa NCT07049575Phase 121 sites📍 Phoenix📍 Fountain Valley📍 Northridge Incyte Corporation · Tests: Ruxolitinib Cream A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa NCT06932003Phase 1, Phase 21 site📍 Beijing Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158 Tablets Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases NCT06599411n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Sampling, Sampling Pelashield™ PainGuard™ vs Restrata® in HS Surgery NCT07316192NA1 site📍 Newark Rutgers, The State University of New Jersey · Tests: Pelashield Painguard A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) NCT06888193Phase 114 sites📍 Santa Monica📍 South Miami📍 Boston UCB Biopharma SRL · Tests: Bimekizumab Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers NCT05994976n/a1 site📍 Montreal Innovaderm Research Inc. · Tests: Blood samples collection, Oral samples collection, Hair samples collection, Skin samples collection (skin tape strip an… A Study of Zasocitinib in Adults With Hidradenitis Suppurativa NCT07244263Phase 249 sites📍 Scottsdale📍 Fort Smith📍 Fountain Valley Takeda · Tests: Zasocitinib (Dose A), Placebo Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. NCT06895499Phase 1, Phase 21 site📍 Jinan Shanghai Huaota Biopharmaceutical Co., Ltd. · Tests: HB0043, HB0043, HB0043 Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia NCT06785779n/a4 sites📍 Riyadh📍 Jeddah📍 Jeddah Novartis Pharmaceuticals · Tests: Secukinmab Real-world Secukinumab Outcomes in Canadian HS Patients NCT07282015n/a15 sites📍 Calgary📍 Calgary📍 Winnipeg Novartis Pharmaceuticals Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. NCT06326476EARLY Phase 11 site📍 Birmingham University of Alabama at Birmingham · Tests: Siplizumab The Safety and Efficacy of Roflumilast Foam in HS NCT07263230Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Roflumilast 0.3% topical foam Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa NCT06058520EARLY Phase 11 site📍 Minneapolis University of Minnesota · Tests: Fecal Microbiota - lyophilized, Placebo drug A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic NCT07123038n/a10 sites📍 San Francisco📍 Stanford📍 Aurora Sonoma Biotherapeutics, Inc. · Tests: Long Term Safety Monitoring Procedures Regulation of Inflammatory Genes in Hidradenitis Suppurativa NCT05507125n/a1 site📍 Birmingham University of Alabama at Birmingham · Tests: Mental health Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa NCT07109765n/a1 site📍 Beijing Peking Union Medical College · Tests: Secukinumab A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa NCT07547813Phase 21 site📍 Warsaw Almirall, S.A. · Tests: LAD328, Placebo Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa NCT07689188Phase 21 site📍 Missouri City Harrison Dermatology · Tests: Roflumilast 0.3% topical foam A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa NCT07213973Phase 230 sites📍 Birmingham📍 Phoenix📍 Phoenix Incyte Corporation · Tests: Povorcitinib Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea NCT07243782n/a1 site📍 Seoul Novartis Pharmaceuticals · Tests: Secukinumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy